Tango Therapeutics (NASDAQ: TNGX) — Perfil da empresa, notícias e dados financeiros
Tango Therapeutics focuses on developing innovative cancer therapies using a precision medicine approach to improve patient outcomes.
Tango Therapeutics
Tango Therapeutics (NASDAQ:TNGX) focuses on discovering and delivering transformative cancer therapies. With a commitment to leveraging the latest in scientific research to address unmet needs in oncology, Tango is dedicated to identifying and exploiting cancer vulnerabilities through a precision medicine approach. Their projects revolve around developing a diverse pipeline of innovative treatment options that aim to improve outcomes for patients with various cancer types. Operating at the intersection of groundbreaking science and patient-centric development, Tango's objectives include advancing these projects through clinical trials, securing regulatory approvals, and ultimately making these therapies available to the patients who need them the most.
Resumo
Operações
Produtos e/ou serviços de Tango Therapeutics
- Development of targeted cancer therapies using CRISPR-based functional genomics to identify novel drug targets.
- Advancement of a personalized cancer vaccine platform for various tumor types.
- Research on small molecule inhibitors targeting synthetic lethal interactions in cancer cells.
- Creation of a suite of bioinformatics tools for the analysis of cancer genomics data.
- Efforts in molecular diagnostics for early cancer detection and treatment decision support.
- Collaboration with pharmaceutical companies to co-develop and bring targeted cancer therapies to market.
equipe executiva do Tango Therapeutics
- Malte PetersPresident, CEO & Director
- Barbara L. WeberExecutive Officer
- Adam S. CrystalPresident of Research & Development
- Alan AshworthFounder & Member of Scientific Advisory Board
- William G. Kaelin Jr.Founder & Member of Scientific Advisory Board
- Antoni RibasFounder & Member of Scientific Advisory Board
- Matthew GallChief Financial Officer
- Jannik N. AndersenChief Scientific Officer
- Elizabeth Pingpank HickinVP of IR & Corporate Communications
- Julie FogartySenior VP, General Counsel & Corporate Secretary
Principais indicadores financeiros
Resultados divulgados pela Tango Therapeutics, em USD.
- Cap. de mercado
- 3,9 bi
- Receita (TTM)
- 53,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- -229.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 62,4 mi | -111,3 mi | -101,6 mi | |
| 42,1 mi | -145,6 mi | -130,3 mi | |
| 36,5 mi | -114,2 mi | -101,7 mi | |
| 24,9 mi | -111,1 mi | -108,2 mi |